Agenda
  • OCT 09, 2019 06:00 AM PDT
    Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities
    Speaker: Brian Rivers, PhD, MPH
  • OCT 09, 2019 07:30 AM PDT
    Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia
    Speaker: Ernesto Diaz-Flores, PhD
  • OCT 09, 2019 09:00 AM PDT
    Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes
    Speaker: Stephen Pennington
    Sponsored By: Agilent
  • OCT 09, 2019 10:30 AM PDT
    A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology
    Speaker: Selena Ferrian
    Sponsored By: IONpath
  • OCT 09, 2019 10:30 AM PDT
    Newly Diagnosed Ovarian Cancer: Surgical Options
    Speaker: Mitchel Hoffman, MD
  • OCT 09, 2019 12:00 PM PDT
    Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer
    Speaker: Anson Tharayanil
  • OCT 09, 2019 12:00 PM PDT
    What is New in Surgical Management of Invasive Bladder Cancer in 2020
    Speaker: Khurshid Guru, MD
  • OCT 09, 2019 01:30 PM PDT
    Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes
    Speaker: Josh Mahlios, PhD
    Sponsored By: Miltenyi Biotec
  • OCT 10, 2019 06:00 AM PDT
    Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells
    Speaker: Jacob Lamberth
    Sponsored By: MilliporeSigma
  • OCT 10, 2019 07:30 AM PDT
    Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families
    Speaker: Ernest Hawk, MD, MPH
  • OCT 10, 2019 09:00 AM PDT
    Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis
    Speaker: Cheng-Zhong Zhang, PhD
  • OCT 10, 2019 09:00 AM PDT
    Next Generation Targets for Immuno-Oncology
    Speaker: Anthony Persen, PhD
    Sponsored By: Bio-Techne
  • OCT 10, 2019 10:30 AM PDT
    Transcriptional Profiling of the Pediatric Tumor Microenvironment
    Speaker: Troy McEachron, PhD
    Sponsored By: NanoString Technologies
  • OCT 10, 2019 10:30 AM PDT
    Whole genome imaging for sensitive and accurate analysis of structural variations in cancer
    Speaker: Sven Bocklandt, PhD
    Sponsored By: Bionano Genomics
  • OCT 10, 2019 12:00 PM PDT
    Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care
    Speaker: Ravindra Kolhe, MD, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2019 01:30 PM PDT
    Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer
    Speaker: Tian Zhang, MD, MHS
  • Novel Cancer Therapeutics and Cancer Prevention
  • OCT 09, 2019 06:00 AM PDT
    Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities
    Speaker: Brian Rivers, PhD, MPH
  • OCT 09, 2019 09:00 AM PDT
    Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes
    Speaker: Stephen Pennington
    Sponsored By: Agilent
  • OCT 09, 2019 10:30 AM PDT
    Newly Diagnosed Ovarian Cancer: Surgical Options
    Speaker: Mitchel Hoffman, MD
  • OCT 09, 2019 12:00 PM PDT
    What is New in Surgical Management of Invasive Bladder Cancer in 2020
    Speaker: Khurshid Guru, MD
  • OCT 10, 2019 06:00 AM PDT
    Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells
    Speaker: Jacob Lamberth
    Sponsored By: MilliporeSigma
  • OCT 10, 2019 07:30 AM PDT
    Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families
    Speaker: Ernest Hawk, MD, MPH
  • OCT 10, 2019 09:00 AM PDT
    Next Generation Targets for Immuno-Oncology
    Speaker: Anthony Persen, PhD
    Sponsored By: Bio-Techne
  • Tumor Drug Resistance and Tumor Evolution
  • OCT 09, 2019 07:30 AM PDT
    Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia
    Speaker: Ernesto Diaz-Flores, PhD
  • OCT 09, 2019 10:30 AM PDT
    A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology
    Speaker: Selena Ferrian
    Sponsored By: IONpath
  • OCT 09, 2019 01:30 PM PDT
    Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes
    Speaker: Josh Mahlios, PhD
    Sponsored By: Miltenyi Biotec
  • OCT 10, 2019 09:00 AM PDT
    Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis
    Speaker: Cheng-Zhong Zhang, PhD
  • OCT 10, 2019 10:30 AM PDT
    Whole genome imaging for sensitive and accurate analysis of structural variations in cancer
    Speaker: Sven Bocklandt, PhD
    Sponsored By: Bionano Genomics
  • OCT 10, 2019 12:00 PM PDT
    Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care
    Speaker: Ravindra Kolhe, MD, PhD
    Sponsored By: QIAGEN
  • Molecular Guidance Versus Standard of Care
  • OCT 09, 2019 12:00 PM PDT
    Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer
    Speaker: Anson Tharayanil
  • OCT 10, 2019 10:30 AM PDT
    Transcriptional Profiling of the Pediatric Tumor Microenvironment
    Speaker: Troy McEachron, PhD
    Sponsored By: NanoString Technologies
  • OCT 10, 2019 01:30 PM PDT
    Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer
    Speaker: Tian Zhang, MD, MHS
OCT 9 - 10 2019

Cancer Research & Oncology 2019

The 7th Annual Cancer Research and Oncology Virtual Event is now available On-Demand! This event focuses on advancements in prevention, diagnosis and treatment of different cancer types.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

The tracks for this year's event include: 

  • Tumor Drug Resistance and Tumor Evolution
  • Radiation Resistance
  • Novel Cancer Therapeutics and Cancer Prevention
    • Health Disparities in Cancer
  • Molecular Guidance Versus Standard of Care

The free online event brings together research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots event, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.

Continuing Education

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 32 credits.

Use #LRcancer to follow the conversation!

 


Speakers
  • Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF
  • Vice President & Division Head for Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center
  • Director, Scientific Affairs, Bionano Genomics
  • Sr.Staff Scientist/LSRP3, Stanford University
  • Surgeon, Dept of Urology, Chair, Dept of Urology, Director, Applied Technology Laboratory for Advanced Surgery, Robert P. Huben Endowed Professor of Oncology, Roswell Park Cancer Institute
  • Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine
  • Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
  • Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine
  • R&D Scientist, Genome and Epigenome Editing: MilliporeSigma
  • Senior Marketing Product Manager, Miltenyi Biotec
  • Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
  • Sr. Director, Protein Business Unit, R&D Systems
  • Director of the Cancer Health Equity Institute Morehouse School of Medicine (MSM)
  • Medical Science Liaison (Urology), Genomic Health, Inc.
  • Assistant Professor, Biomedical Informatics, Harvard Medical School , and Assistant Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute
  • Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute

Show Resources
You May Also Like
NOV 14, 2019 06:00 AM PST
C.E. CREDITS
NOV 14, 2019 06:00 AM PST
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2019 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
JUN 20, 2019 06:00 AM PDT
C.E. CREDITS
JUN 20, 2019 06:00 AM PDT
LabRoots and the Precision Medicine Planning Committee are pleased to announce the 4th Annual Precision Medicine Virtual Event. Precision Medicine 2019, a two-day event held June 19-20, will...
SEP 26, 2019 06:00 AM PDT
C.E. CREDITS
SEP 26, 2019 06:00 AM PDT
LabRoots and the Cell Biology Planning Committee are please to announce the 3rd Annual Cell Biology Virtual Event, providing an opportunity to discuss recent discoveries in biological researc...
AUG 22, 2019 06:00 AM PDT
C.E. CREDITS
AUG 22, 2019 06:00 AM PDT
LabRoots is pleased to announce a new addition to our virtual conference line up for 2019, Forensics & Toxicology! The exciting field of Forensics/Toxicology is focused on a blend of biology...
SEP 11, 2019 06:00 AM PDT
C.E. CREDITS
SEP 11, 2019 06:00 AM PDT
LabRoots and the Microbiology Planning Committee is bringing the microbiology research community together at the 5th Annual Microbiology and Immunology Virtual Event! During the free, two-day...
NOV 12, 2020 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
Speakers

  • Ernesto Diaz-Flores, PhD
    Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF
    Biography
      Ernesto Diaz-Flores, PhD, is an Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF. He is an experienced biochemist with a focus on identifying novel therapeutics for high-risk childhood leukemia. Dr. Diaz-Flores obtained his BsC in Biochemistry at the Universidad Complutense (Madrid) and his PhD in molecular biology for his studies of lymphocyte activation at the Universidad Autonoma (Madrid). He came to UCSF for his postdoctoral studies first under the supervision of Dr Kevin Shannon, studying murine models of Kras leukemia and then pursuing a second postdoctoral fellowship in Dr. Mignon Loh's laboratory. Dr Diaz-Flores specializes in identifying novel therapies for children with hypodiploid leukemia. His work combines the study of dysregulated signaling networks, transcriptomics analysis and drug assays. He further validates drugs with therapeutic potential running in vivo preclinical trials using patient derived xenografted models. His latest work has informed a clinical trial for patients with high-risk leukemia
    • Ernest Hawk, MD, MPH
      Vice President & Division Head for Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center
      Biography
        Ernest Hawk, MD, MPH, is vice president and division head for Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment which fuels critical prevention research initiatives and infrastructures of the center, as well as service as co-leader of MD Anderson's Cancer Prevention and Control Platform. The Platform plans, implements, and evaluates evidence-based actions in public policy, professional/public education, and community-based service delivery to reduce cancer and related risk factors at the population level. His personal research interests over the last two decades include preclinical and clinical drug development for cancer prevention, the conduct of a variety of clinical trials in cancer prevention, and the inclusion of diverse and underserved populations in cancer clinical trials, clinical research, and cancer control programs to improve outcomes and promote equity. He earned his medical degree from Wayne State University and his MPH degree from Johns Hopkins University. Additionally, he received training in internal medicine and served as a staff physician at Emory University, completed a medical oncology fellowship at the University of California, San Francisco, and completed a cancer prevention fellowship at the National Cancer Institute.
      • Sven Bocklandt, PhD
        Director, Scientific Affairs, Bionano Genomics
        Biography
          Dr. Sven Bocklandt is a human geneticist with a background in gene discovery. He received his PhD from the University of Antwerp, Belgium, based on research on the genetic components of brain sexual differentiation performed at the National Cancer Institute, and at the University of California Los Angeles. As Director of Scientific Affairs at Bionano Genomics, he focuses on the scientific discoveries made on the Bionano platform and is leading clinical validation studies on Bionano's performance in genetic disease and cancer diagnostics.
        • Selena Ferrian
          Sr.Staff Scientist/LSRP3, Stanford University
          Biography
            Prior to Stanford Selena worked as a Research Scientist within the Immunotherapy Platform, led by Nobel laureate Professor James Allison at MD Anderson Cancer Center, where she analyzed and interpreted data for immunotherapy clinical trials and implemented an imaging technology to study the immune landscape in metastatic renal cell carcinoma. As a Sr. Scientist at Stanford University, Selena is interested in investigating the role of glioma infiltrating macrophages in disease pathogenesis. More specifically, she wants to understand how cell-cell communication affects macrophage cell types and states in Glioblastoma in order to accelerate future immunotherapy strategies. Concomitantly Selena is overseeing and supporting Dr. Angelo's research collaborations derived from the implementation of the MIBI technology in diseased tissue.
          • Khurshid Guru, MD
            Surgeon, Dept of Urology, Chair, Dept of Urology, Director, Applied Technology Laboratory for Advanced Surgery, Robert P. Huben Endowed Professor of Oncology, Roswell Park Cancer Institute
            Biography
              Khurshid A. Guru, MD, was appointed Director of Robotic Surgery at Roswell Park Cancer Institute (RPCI) in October 2005 and Chair, Department of Urology in June 2017. Dr. Guru completed his residency training in Urologic Surgery (2005) and a Robotic Surgery Fellowship (2004), Henry Ford Health System, MI. He also completed an International Fellowship in Urologic-Oncology (2004) at the Urology and Nephrology Center at Mansoura University, Mansoura, Egypt. Dr. Guru is one of the early fellowship-trained robotic surgeons (2004) with an experience of over 10,000 surgical console hours and has performed over 2,500 procedures. Dr. Guru performed one of the first robot-assisted radical cystectomy in the world, and has worked in development and evolution of oncologic safety and efficacy of minimally invasive approaches to bladder cancer. Dr. Guru has performed live demonstrations of robotic surgery in eleven countries at international seminars. His experience in robot-assisted surgery, especially his 600 robot-assisted radical cystectomies, has been shared with over 400 surgeons from more than 15 countries. His research interest has also been in the application of robotic surgery for urinary reconstruction. Dr. Guru developed one of the first robotic surgical simulators and works extensively in safe human machine interface, cognitive interaction and developing safe environments during robot-assisted surgery. Dr. Guru developed the first validated robotic surgery curriculum for safe transfer of surgical skills for future robotic surgeons. His major interest is bladder cancer and robotic surgical education and its incorporation. He leads the International Robotic Cystectomy Consortium with over 55 surgeon members in over 23 countries. He also leads the Applied Technology Laboratory for Advanced Surgery (ATLAS) Program at RPCI. Dr. Guru is a member of the American Urological Association, Cancer Society of Kashmir. He founded a non-profit foundation in 2007 which supports health and education related programs in Kashmir. His foundation supports children in government run schools in his native home, Kashmir. He has authored and co-authored over 250 several journal articles, abstracts and book chapters.
            • Mitchel Hoffman, MD
              Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine
              Biography
                Dr. Hoffman is a full-time faculty member in the Department of Gynecologic Oncology at Moffitt Cancer Center, and Professor at USF Morsani College of Medicine. He was Director of Medical Student Education in Obstetrics and Gynecology from 1987-1999, and Director of the Division of Gynecologic Oncology and Program Director of the Gynecologic Oncology Fellowship Training Program from 1999-2015. He is the author of one textbook, over 250 articles in scientific journals, and 21 textbook chapters. He is an examiner for the American Board of Obstetrics and Gynecology. Dr. Hoffman has been president of the South Atlantic Association of Obstetricians and Gynecologists and The Society of Pelvic Surgeons.
              • Ravindra Kolhe, MD, PhD
                Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
                Biography
                  Currently, Dr.Ravindra Kolhe is an Associate Professor in the Department of Pathology at the Augusta University in Augusta, Georgia, and divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching, and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory. As a Molecular and Genetic Pathologist, he is actively engaged in molecular and cytogenetic evaluation of patient samples as a part of the multi- disciplinary clinical team treating patients in a personalized and precision medicine model. As a Breast Pathologist, he provides expert opinions for the breast multidisciplinary tumor boards, consultation and second opinion to difficult breast cancer patients referred to Georgia Cancer Center. Dr. Kolhe is an physician-scientist with expertise in basic mechanisms of tumor immunology, including tolerogenic DCs, Tregs, and the indoleamine 2,3-dioxygenase pathway He has over 160 publications, including peer-reviewed articles, abstracts and invited reviews most in the realm of the molecular pathology of various malignancies.
                • Troy McEachron, PhD
                  Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine
                  Biography
                    Dr. McEachron received his PhD in Cellular and Molecular Pathology from the University of North Carolina at Chapel Hill and completed postdoctoral training at both the St. Jude Children's Research Hospital and at the Translational Genomics Research Institute. Dr. McEachron is currently an Assistant Professor in the Department of Translational Genomics and the Department of Pediatrics at the Keck School of Medicine of the University of Southern California. Dr. McEachron's research employs integrated multi-parametric approaches to reveal how the genomic complexity of pediatric osteosarcoma influences the tumor microenvironment and, in response, how the microenvironment supports the growth of such genomically unstable tumors. Dr. McEachron's research interests reflect his diverse training history which includes the molecular dissection of autocrine and paracrine signaling mechanisms between tumor and host using in vitro and in vivo models, the characterization of genetically engineered mouse models of pediatric brain tumors, and the interpretation and functional validation next generation sequencing data from recurrent/refractory pediatric cancer patients for clinical decision making.
                  • Jacob Lamberth
                    R&D Scientist, Genome and Epigenome Editing: MilliporeSigma
                    Biography
                      Jacob has been working on developing and testing Cas9 products in the Genome Engineering team at MilliporeSigma since joining the company in 2015. He has led the R&D testing and has evaluated dozens of CRISPR systems, on top of helping Quality Control testing of the CRISPR products that MilliporeSigma currently sells. Recently he has focused on the development of multiple Cas9 Ribonucleoproteins and their potential therapeutic applications. Before joining MilliporeSigma, Jacob worked as a lab technician and research assistant in the Brickner Lab at Northwestern University
                    • Josh Mahlios, PhD
                      Senior Marketing Product Manager, Miltenyi Biotec
                      Biography
                        Josh Mahlios is a Senior Marketing Product Manager at Miltenyi Biotec, responsible for cell separation technologies and immunology focused applications. In these roles, he drives the awareness and adoption of the reagents and instrumentation specifically developed for both basic and translational researchers investigating the immune system. Prior to joining Miltenyi Biotec in 2016, Josh was a postdoctoral scholar at Stanford University.
                      • Stephen Pennington
                        Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
                        Biography
                          Steve is Professor of Proteomics at University College Dublin, Ireland. A chemist (Imperial College, London) and PhD biochemist (University of Cambridge) by training. Through engagement in a series of collaborations and international consortia, his current biomedical proteomics research is directed to the discovery and development of protein biomarkers. On-going projects are focussed on the mass spectrometry based measurement and evaluation of protein biomarkers in oncology and inflammatory disease to progress them to clinical utility. Steve's team are also investigating the mechanisms of disease progression focussing on prostate cancer and psoriatic arthritis. Steve is highly energetic and enthusiastic with an innovative, open and inclusive approach to his work. He has given over 200 invited presentations at international events, published over 80 scientific papers, edited and contributed to several books including editing one of the first books on Proteomics that was translated into Chinese and Japanese. Steve has held roles as a committee member in the British Society for Proteome Research (currently vice-President, and the European Proteomics Association. He is the lead organiser of the forthcoming annual world congress of the Human Proteome Organisation (HUPO) that will be held in the national Convention Centre in Dublin from 17-21st September 2017 (www.hupo2017.ie). Recently, Steve founded the UCD spinout company 'Atturos' (Dec 2016) to support the delivery of OCProDx to clinical use. OCProDx is a prostate cancer blood-based biomarker test that has the capability to distinguish patients with organ-confined and non-organ confined disease. The test will help inform men diagnosed with prostate cancer whether they should go on or stay on 'active surveillance' The Atturos team has the expertise and experience to deliver this and other multiplexed protein biomarker tests to market.
                        • Anthony Persen, PhD
                          Sr. Director, Protein Business Unit, R&D Systems
                          Biography
                            Anthony received his Ph.D. in Cell Biology and Anatomy at the University of Arizona where his research concentrated on understanding the molecular mechanisms of cardiac valve development. He moved onto a Postdoctoral Research Fellowship at the University of Minnesota where he utilized zebrafish and mouse model systems to uncover new genes involved in kidney and heart development and also published the genetic cause of the dwarfing syndrome in humans called dominant Robinow Syndrome. Anthony spent time in the Stem Cell biotech industry using mRNA overexpression to reprogram somatic cells to pluripotency as well as transdifferentiating one cell type into another. Finally, Anthony has been at R&D Systems for the last 8 years working as a Manager and then Director in the Protein Development Department. Anthony has over 12 years of Biotech industry experience and is focused on offering the highest quality recombinant proteins to customers. New protein product offerings in the Immuno-oncology area is a major focus for R&D Systems as so many academic and biotech/pharma labs are entering this area with the success of both antibody immunotherapy as well as CAR T or CAR NK research and therapies.
                          • Brian Rivers, PhD, MPH
                            Director of the Cancer Health Equity Institute Morehouse School of Medicine (MSM)
                            Biography
                              Dr. Rivers is the Director of the Cancer Health Equity Institute at Morehouse School of Medicine (MSM). Dr. Rivers is nationally and internationally recognized as a leader in cancer disparities research and currently serves as a member of the National Institutes of Health (NIH) National Advisory Council on Minority Health and Health Disparities (NACMHD). Dr. Rivers is an active member in the American Association for Cancer Research (AACR) community and regularly serves on the faculty for the Scientist to Survivor program. More recently, Dr. Rivers was elected to serve as Chairperson for the Minorities in Cancer Research Council of the AACR. Dr. Rivers is a behavioral scientist with a broad background in implementation science and public health, with specific training and expertise in health behavior research methodologies for addressing health disparities, such as the lay health model and Community-based Participatory Research framework. Dr. Rivers' specific program of research is focused on addressing prostate cancer disparities among African Americans and exploring the role of novel communication interventions, such as mobile health technology. Currently, Dr. Rivers is leading several large randomized controlled trials, funded by NIH and NIMHD R01, to evaluate and characterize app usage and acceptability for education and care coordination among African American men diagnosed with prostate cancer. Dr. Rivers is Multiple-Principal Investigator for the NIH NCI funded U54 Cancer Research Partnership between MSM, Tuskegee University, and the University of Alabama-Birmingham Comprehensive Cancer Center (UAB CCC). Dr. Rivers also directs the Integrating Special Populations Program of the NIH NCATS funded Georgia Clinical and Translational Science Alliance.
                            • Anson Tharayanil
                              Medical Science Liaison (Urology), Genomic Health, Inc.
                              Biography
                                Anson Tharayanil graduated from University of California, Davis with a degree in Biological Sciences. With over a decade of experience in the biotechnology space, he has helped bring several multigene signature tests for breast, colon, and prostate cancer into clinical use. His passion is in educating both physicians and patients on the use and value of genomic tests to optimize cancer care.
                              • Cheng-Zhong Zhang, PhD
                                Assistant Professor, Biomedical Informatics, Harvard Medical School , and Assistant Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute
                                Biography
                                  Cheng-Zhong Zhang obtained a Ph.D. in Chemical Engineering with a minor in Physics from Caltech. He received postdoctoral training in single-molecule biophysics in Timothy Springer's laboratory at Harvard Medical School and subsequently worked on single-cell genomics and cancer biology in Matthew Meyerson's laboratory at the Broad Institute of Harvard and MIT and at Dana-Farber Cancer Institute. He combines single-cell genomic analysis and cell biology to study genome evolution and phenotypic variation. Currently he focuses on the mechanisms and the transcriptional consequences of chromosomal abnormalities, such as rearrangement and aneuploidy, and how such events may promote tumor development.
                                • Tian Zhang, MD, MHS
                                  Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute
                                  Biography
                                    Dr. Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School and completed residency in internal medicine and fellowship in hematology/oncology at Duke University. She is currently an Assistant Professor within the Division of Medical Oncology at Duke, specializing in genitourinary (GU) malignancies. She actively leads both clinical and translational research studies in the GU oncology and Phase I groups. She is the overall study chair for the phase 3 PDIGREE trial for metastatic renal cell carcinoma in the Alliance cooperative group and also serves as PI for several investigator-initiated trials in prostate and bladder cancer at Duke. She is committed to improving novel therapies and biomarkers for patients with GU malignancies.
                                  Sponsored By

                                  For information on becoming a sponsor or exhibitor, please click here.


                                  C.E. Credits

                                  The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                  Posters

                                  POSTER SUBMISSION GUIDELINES

                                  Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


                                  SUBMIT YOUR ABSTRACT

                                  Enter the following information to this Submission Form:

                                  • Poster Title
                                  • Your Name
                                  • Your Institution
                                  • Your Email
                                  • Abstract describing the poster


                                  All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

                                  If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                  Questions? Email Posters@LabRoots.com

                                  LabRoots Policy

                                  Committee

                                  To download the Program Committee brochure here.


                                  • David Albala

                                    Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                    See more See less
                                  • Antonio Baines

                                    Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                    See more See less
                                  • Rajan Gupta

                                    Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                    See more See less
                                  • Keith Knutson

                                    Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of ...

                                    See more See less
                                  • Jonas Korlach

                                    Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He ...

                                    See more See less
                                  • Martin Latterich

                                    The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                    See more See less
                                  • Thomas Polascik

                                    Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                                    See more See less
                                  • Khyati Shah

                                    Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                                    See more See less
                                  Help

                                  General LabRoots Questions

                                  For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                  Contact us

                                  Virtual Events and Webinars

                                  Supported Configurations

                                  • Operating System Internet Explorer Firefox Chrome Safari
                                    Vista IE8+ FF10+ Chrome15+
                                    Windows 7 IE8+ FF10+ Chrome15+
                                    Windows 8 IE10 FF10+ Chrome15+
                                    Mac OS X   FF10+ Chrome15+ Safari5.1+
                                  • Cookie settings: session cookies enabled
                                  • Browser configuration must have JavaScript enabled
                                  • Adobe Flash player 10.2 or later

                                  To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                  Internet Connection

                                  • A minimum of 100Kbps is recommended for audio-only events
                                  • A minimum of 300Kbps is recommended for speaker on-video events

                                  Computer Equipment

                                  • Screen Resolution: Minimum 1024x768
                                  • Video Card: 65,000 colors minimum
                                  • Sound card and speakers (or headphones) for hearing webcast in full format
                                  • Audio Card: 16-bit minimum
                                  • RAM: 512MB of free RAM

                                  Firewall Protocol

                                  • HTTP on port 80 or HTTPS on port 443
                                  • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                  • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                  Work-At-Home Attendees

                                  • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                  For A Seamless Experience

                                  When using a mobile device, FREE Mobile Apps are available:

                                  - For viewing Webinars:

                                  - For viewing Virtual Events

                                  Attendee Guide

                                  • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                  Virtual Event and Webinar Support:

                                  Continuing Education (CME/CE) Support

                                  Loading Comments...
                                  Show Resources